AJMC® in the Press, March 1, 2019

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Adults with hypertrophic cardiomyopathy living in lower-income or more socially deprived areas experienced significantly higher risks of heart failure, arrhythmias, stroke, and death.

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

Black adolescents from lower-income households who engage in volunteer activities experience reduced odds of developing diabetes in adulthood.

Poland’s LiBRha project will expand liquid biopsy and molecular testing nationwide to improve diagnosis, monitoring, and outcomes for children with soft tissue sarcoma.